DLA Piper has advised a consortium of South Korean investors working with asset manager Mastern Investment Management on the EUR 375 acquisition, made as part of a joint venture with Munich-based asset manager Wealthcore Invester Management, of the Hilton Parkview Vienna. The sellers — two Austrian family firms — were represented by Invester United Benefits and advised by Schoenherr.
In the shadow of Brexit negotiations, the European Parliament agreed on 14 February 2019 to set up an EU level tool to screen FDIs on grounds of security or public order to protect sectors. The new "Regulation (EU) 2019/452 establishing a framework for screening of foreign direct investments into the European Union" (EU-FDI Regulation) shall apply from 11 October 2020 and be binding in its entirety as well as directly applicable in all member states.
PHH has advised outside creditors Helaba and the European Investment Bank on the Educational Campuses project in Vienna, which takes the form of a public-private partnership with winning bidders HYPO NOE and Strabag. Eisenberger & Herzog advised HYPO NOE and Strabag on the deal, which is valued at over EUR 100 million.
Eisenberger & Herzog has announced that Senior Partner Georg Eisenberger will leave the Austrian firm on June 30, 2020, after twenty-five years of partnership, to establish a boutique law firm for administrative, constitutional, and European law, specializing in public commercial law and unique legal cases. In addition to its headquarters in Graz, the firm will also have an office in Brussels.
In a recent case involving parallel-imported agrochemical products, the District Court of The Hague ruled that non-compliance with the requirements laid down by the European Court of Justice (CJEU) for parallel import of relabelled products displaying the original right-holder’s trademark constitutes trademark infringement, particularly if the right-holder is not properly notified of the parallel import and is not offered a sample of the relabelled product on request. This decision shows that the requirements for parallel import are applied strictly by the courts and have a broad scope (not limited to pharmaceutical products), allowing the mark-holder to exercise control over the resale, re-labelling, and re-packaging of its original products within the EU.